Skip to main content

Master of Public Health

Enterovirus D68-Associated Acute Respiratory Illness - New Vaccine Surveillance Network, United States, July-October, 2017 and 2018

AUTHORS

Kujawski SA , Midgley CM , Rha B , Lively JY , Nix WA , Curns AT , Payne DC , Englund JA , Boom JA , Williams JV , Weinberg GA , Staat MA , Selvarangan R , Halasa NB , Klein EJ , Sahni LC , Michaels MG , Shelley L , McNeal M , Harrison CJ , Stewart LS , Lopez AS , Routh JA , Patel M , Oberste MS , Watson JT , Gerber SI , . MMWR. Morbidity and mortality weekly report. 2019 3 29; 68(12). 277-280

ABSTRACT

In the fall of 2014, an outbreak of enterovirus D68 (EV-D68)-associated acute respiratory illness (ARI) occurred in the United States (1,2); before 2014, EV-D68 was rarely reported to CDC (2,3). In the United States, reported EV-D68 detections typically peak during late summer and early fall (3). EV-D68 epidemiology is not fully understood because testing in clinical settings seldom has been available and detections are not notifiable to CDC. To better understand EV-D68 epidemiology, CDC recently established active, prospective EV-D68 surveillance among pediatric patients at seven U.S. medical centers through the New Vaccine Surveillance Network (NVSN) (4). This report details a preliminary characterization of EV-D68 testing and detections among emergency department (ED) and hospitalized patients with ARI at all NVSN sites during July 1-October 31, 2017, and the same period in 2018. Among patients with ARI who were tested, EV-D68 was detected in two patients (0.8%) in 2017 and 358 (13.9%) in 2018. Continued active, prospective surveillance of EV-D68-associated ARI is needed to better understand EV-D68 epidemiology in the United States.

Tags: